SELLAS Life Sciences Group Inc sell Vassago1
Start price
26.03.24
/
50%
€1.06
Target price
26.03.25
-
Performance (%)
-1.69%
End price
31.03.24
€1.05
Summary
This prediction ended on 31.03.24 with a price of €1.05. With a performance of -1.69%, the SELL prediction for SELLAS Life Sciences Group Inc by Vassago1 was down slightly. Vassago1 has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| SELLAS Life Sciences Group Inc | -5.028% | -5.028% |
| iShares Core DAX® | 2.594% | -1.158% |
| iShares Nasdaq 100 | 3.553% | -1.727% |
| iShares Nikkei 225® | 0.687% | -8.354% |
| iShares S&P 500 | 2.209% | -0.942% |
According to Vassago1 what are the pros and cons of SELLAS Life Sciences Group Inc for the foreseeable future?
Pros
Cons
Risky Investment
Comments by Vassago1 for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Sell SELLAS Life Sciences Group Inc
In the thread Trading SELLAS Life Sciences Group Inc
Stopped prediction by Vassago1 for SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€1.46
02.03.23
02.03.23
-
02.03.24
02.03.24
4.01%
05.03.23
05.03.23
